Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

Who is this study for? Patients with Type 2 Diabetes
Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 60
Healthy Volunteers: t
View:

• Age 21-60

• A1C ≤ 8.5%

• Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)

• On stable dose of oral hypoglycemic agents \>4 months

• On stable dose of other medications for \>4 months

Locations
United States
Virginia
University of Virginia
RECRUITING
Charlottesville
Contact Information
Primary
Lee Hartline, MEd
lmh9d@virginia.eud
434-924-5247
Backup
Linda Jahn, RN, MEd
las6e@virginia.edu
434-924-1134
Time Frame
Start Date: 2019-02-28
Estimated Completion Date: 2025-12
Participants
Target number of participants: 60
Treatments
Experimental: Exercise Alone
16 weeks of treatment
Experimental: Liraglutide alone
16 weeks of treatment
Experimental: Exercise + Liraglutide
16 weeks of treatment
Related Therapeutic Areas
Sponsors
Collaborators: American Diabetes Association, National Institutes of Health (NIH)
Leads: University of Virginia

This content was sourced from clinicaltrials.gov